Lexicon Pharmaceuticals regains Nasdaq compliance for minimum bid price

Published 28/07/2025, 12:46
Lexicon Pharmaceuticals regains Nasdaq compliance for minimum bid price

Lexicon Pharmaceuticals , Inc. (NASDAQ:LXRX) announced Monday that it has regained compliance with the minimum $1 bid price requirement for its common stock on The Nasdaq Global Select Market. The company reported that it received a letter from Nasdaq’s Listing Qualifications staff on July 23 confirming the compliance and stating that the matter regarding its previous failure to meet the requirement is now closed.

The information is based on a press release statement included in a recent SEC filing. Investors anticipating Lexicon’s next earnings report on August 6 can access additional insights through InvestingPro, which offers 12 more exclusive tips and comprehensive analysis in the Pro Research Report, helping investors make informed decisions about this biotech company.

In other recent news, Lexicon Pharmaceuticals reported its Q1 2025 earnings, which showed a smaller-than-expected loss per share but a significant drop in revenue compared to forecasts. The company posted an EPS of -$0.07, surpassing the projected -$0.12. However, revenue reached only $1.26 million, falling short of the anticipated $2.82 million. Despite the EPS beat, the revenue shortfall has raised investor concerns. Additionally, Lexicon Pharmaceuticals announced it has received an extension from Nasdaq to regain compliance with the minimum $1 bid price requirement for its common stock. The company now has until December 30, 2025, to meet this requirement. This extension was granted after Lexicon applied to transfer its common stock listing to the Nasdaq Capital Market, a move approved by Nasdaq. These developments highlight ongoing challenges and adjustments within the company.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.